10 Best Small-Cap Biotech Stocks to Buy According to Analysts

5. Vera Therapeutics, Inc. (NASDAQ:VERA)

Number of Hedge Fund Holders: 40

Upside Potential: 108.97%

Vera Therapeutics, Inc. (NASDAQ:VERA) is one of the best small-cap biotech stocks to buy according to analysts.

On November 10, 2025, The Fly reported that H.C. Wainwright increased its price target on Vera Therapeutics, Inc. (NASDAQ:VERA) from $85 to $90, while maintaining a “Buy” rating. The bullish stance reflects the company’s presentation of findings from its ongoing ORIGIN 3 study with atacicept. The investment firm expects a 95% likelihood of atacicept’s launch in IgA nephropathy (IgAN), anticipating the drug to generate $56 million in revenue in the first year, with growth to $2.5 billion by 2033.

On November 6, 2025, Vera Therapeutics, Inc. (NASDAQ:VERA) presented successful Phase 3 trial results for its late-stage kidney disease treatment. The data, presented at the American Society of Nephrology Kidney Week, revealed a 46% decrease in proteinuria along with strong safety outcomes. These results highlight the potential of this therapy to improve the management of chronic renal diseases. To evaluate the study’s impact and plan forthcoming regulatory actions, the company hosted an in-depth conference call with key opinion leaders.

The announcement strengthened investor confidence and suggested growing regulatory progress, with Vera advancing towards filing its Biologics License Application (BLA) for U.S. review. The company’s solid clinical results were validated by peer-reviewed recognition, reinforcing its credibility in nephrology and potentially paving the way for wider market acceptance when the therapy is launched.

Vera Therapeutics, Inc. (NASDAQ:VERA) is focused on developing therapies for severe immunological and renal diseases.